PVCT Financial Facts

Total operating loss: -5.78M
Research and development: 2.46M
See Full Income Statement

Total Stockholders' Equity: 5.31M
Accounts payable - trade: 1.49M
See Full Balance Sheet

Provectus Biopharma (PVCT) Earnings

  |   Expand Research on PVCT
Next EPS Date N/A EPS Growth Rate N/A
Average EPS % Beat Rate N/A Revenue Growth Rate N/A
Average % Move 1-Wk after EPS N/A Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/14/25 Q225 N/AN/A N/A N/AN/A N/A N/A N/A
11/18/24 Q424 N/AN/A N/A N/AN/A N/A N/A N/A
11/14/24 Q324 $0.00N/A N/A $110KN/A N/A Details
11/8/24 Q324 N/AN/A N/A N/AN/A N/A N/A N/A
8/26/24 Q224 N/AN/A N/A N/AN/A N/A N/A N/A
8/19/24 Q224 N/AN/A N/A N/AN/A N/A N/A N/A
8/12/24 Q224 N/AN/A N/A N/AN/A N/A N/A N/A
8/7/24 Q224 N/AN/A N/A N/AN/A N/A N/A N/A